Abstract library

29 results for "Srirajaskanthan".
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#376 Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
Introduction: Small bowel neuroendocrine tumors are uncommon tumors with an incidence of <0.5-1 per 100,000 population/year. We report on the survival rates of patients who had the primary tumor resected, to see whether primary tumor removal improves outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#377 Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors
Introduction: Small bowel neuroendocrine tumors (SB NETs) have a reported incidence of approximately 0.5-1 per 100 000 population/yr.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#378 Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?
Introduction: Small bowel (SB) NETs are regarded as relatively indolent cancers. ENETS has published TNM staging. This study aims to demonstrate whether the TNM stage predicts survival in this cohort of patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Keywords: TNM, survival
#575 Does the ENETS TNM staging criteria predict survival in patients with small bowel neuroendocrine tumours?
Introduction: A TNM staging system was designed by ENETS to stage small bowel NETs .(SBNETs)
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical
Presenting Author: Dr Rajaventhan Srirajaskanthan
Keywords: Staging
#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#773 Thymosin β4 as Putative Marker in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETS) arise from the diffuse endocrine system which produce biogenic amines and peptides that could be potential biomarker. We previously analysed proteomes secreted by NET cell lines and identified mac2BP as a putative marker which was also elevated in patients compared to healthy controls.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Dalvinder Mandair
Authors: Mandair D, Marotta D, Ho J, Waugh M, ...
Keywords: proteomics
#890 Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors
Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver